By Fineline Cube 
CANbridge Pharmaceuticals (HKG: 1228) announced on August 13, 2025, that it has entered into a share subscription agreement with Baheal Pharmaceutical Group (SHE: 301015). The agreement involves issuing shares at a price of HKD 1.34 per share, raising a total of HKD 100 million. This strategic equity financing aims to optimize CANbridge’s commercial operations and strengthen its market capabilities.
Strategic Equity Financing
The equity financing is designed to enhance CANbridge’s commercial infrastructure and capabilities. The funds will be utilized to advance the company’s commercial objectives and reinforce its position in the rare disease market.
Commercial Services Agreement
In addition to the equity investment, CANbridge and Baheal Pharma have signed an exclusive commercial services agreement. Under this agreement, a subsidiary of Baheal Pharma will act as the exclusive commercial service provider for certain CANbridge products in mainland China, Hong Kong, and Macau. An affiliate of Baheal Pharma also has the option to serve as a distributor in these regions.
Expected Outcomes
This collaboration and equity investment are expected to solidify CANbridge’s leading position in the domestic rare disease market. The partnership leverages Baheal Pharma’s commercial expertise and market presence to expand CANbridge’s product reach and enhance its commercial performance.-Fineline Info & Tech